4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

or therapeutic medical strategies. However, the ESC Guidelines do not override in any way
whatsoever the individual responsibility of health professionals to make appropriate and …

Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium
not secondary to ischemic, hypertensive, or valvular heart disease. ACM incorporates a …

The recommendations listed in this clinical practice guideline are, whenever possible,
evidence-based. An initial extensive evidence review, which included literature derived from …

Myocardial diseases are associated with an increased risk of potentially fatal cardiac
arrhythmias and sudden cardiac death/cardiac arrest during exercise, including hypertrophic …

Arrhythmogenic cardiomyopathy is an inherited heart muscle disorder, predisposing to
sudden cardiac death, particularly in young patients and athletes. Pathological features …

Myocardial strain is a principle for quantification of left ventricular (LV) function which is now
feasible with speckle-tracking echocardiography. The best evaluated strain parameter is …

In this scientific statement from the American Heart Association, experts in the field of
cardiomyopathy (heart muscle disease) in children address 2 issues: the most current …

442 Circulation August 4, 2015 largely composed of patients referred because of their
highrisk status or severe clinical manifestations requiring specialized therapeutic …